Matrix Metalloproteinases as Biomarkers and Treatment Targets in Mesothelioma: A Systematic Review.
biomarker
drug target
genetic variability
mesothelioma
metalloproteinases
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
25 08 2021
25 08 2021
Historique:
received:
30
07
2021
revised:
20
08
2021
accepted:
23
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
14
1
2022
Statut:
epublish
Résumé
Metalloproteinases (MMPs) have an important role in tissue remodeling and have been shown to have an effect on tumor progression, invasion, metastasis formation, and apoptosis in several tumors, including mesothelioma. Mesothelioma is a rare tumor arising from pleura and peritoneum and is frequently associated with asbestos exposure. We have performed a systematic search of PubMed.gov and ClinicalTrials.gov databases to retrieve and review three groups of studies: studies of MMPs expression in tumor tissue or body fluids in patients with mesothelioma, studies of MMPs genetic variability, and studies of MMPs as potential novel drug targets in mesothelioma. Several studies of MMPs in mesothelioma tissues reported a link between higher expression levels of commonly studied MMPs and clinical parameters, such as overall survival. Fewer studies have investigated genetic variability of
Identifiants
pubmed: 34572485
pii: biom11091272
doi: 10.3390/biom11091272
pmc: PMC8469122
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Matrix Metalloproteinases
EC 3.4.24.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Cancer Res. 2012 May 1;18(9):2478-89
pubmed: 22371455
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33
pubmed: 17318226
Cancer Genomics Proteomics. 2020 May-Jun;17(3):225-236
pubmed: 32345664
Oncotarget. 2018 Apr 10;9(27):19273-19282
pubmed: 29721201
Enzyme Protein. 1996;49(1-3):7-19
pubmed: 8796994
Clin Cancer Res. 2006 May 1;12(9):2862-8
pubmed: 16675582
Int Arch Occup Environ Health. 2019 Oct;92(7):949-957
pubmed: 30993422
Arthritis Res Ther. 2003;5(1):12-24
pubmed: 12716443
J Cell Physiol. 2006 May;207(2):540-52
pubmed: 16447244
BMC Cancer. 2012 Mar 28;12:121
pubmed: 22455335
Eur Respir J. 2011 Jul;38(1):191-208
pubmed: 21177845
Exp Mol Pathol. 2011 Feb;90(1):91-6
pubmed: 20969861
Dis Markers. 2019 May 2;2019:1242964
pubmed: 31191742
Dis Markers. 2017;2017:8069529
pubmed: 29138529
Thorac Surg Clin. 2020 Nov;30(4):395-423
pubmed: 33012429
Int J Cancer. 2009 Sep 15;125(6):1473-8
pubmed: 19507256
Br J Cancer. 2003 May 19;88(10):1553-9
pubmed: 12771921
Cardiovasc Res. 2006 Feb 15;69(3):562-73
pubmed: 16405877
Sci Rep. 2019 Jan 17;9(1):197
pubmed: 30655550
Int J Environ Res Public Health. 2020 Sep 21;17(18):
pubmed: 32967259
Oncol Rep. 2009 Dec;22(6):1283-91
pubmed: 19885578
J Natl Compr Canc Netw. 2016 Jul;14(7):825-36
pubmed: 27407123
J Surg Res. 2013 Aug;183(2):517-23
pubmed: 23465389
Radiol Oncol. 2018 Feb 7;52(2):160-166
pubmed: 30018519
Eur Respir J. 2010 Feb;35(2):381-90
pubmed: 19643940
J Bronchology Interv Pulmonol. 2014 Oct;21(4):327-34
pubmed: 25321452
Cell Prolif. 2010 Apr;43(2):114-23
pubmed: 20447056
Exp Lung Res. 2006 Mar-Apr;32(3-4):69-79
pubmed: 16754473
Sci Rep. 2020 Oct 7;10(1):16678
pubmed: 33028834
J Enzyme Inhib Med Chem. 2016;31(sup1):177-183
pubmed: 27028474
Circ Res. 2003 May 2;92(8):827-39
pubmed: 12730128
PLoS One. 2009 Sep 15;4(9):e7016
pubmed: 19753302
Ind Health. 2007 Jun;45(3):379-87
pubmed: 17634686
Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):163-70
pubmed: 18199721
G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):335-8
pubmed: 18409713
Mol Cell Biochem. 2019 May;455(1-2):195-206
pubmed: 30564960